CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
Ceribell, Inc. (CBLL) is the issuer in a notice under Rule 144 filed for planned sales of its common stock by holder Xingjuan Chao. The filing lists an upcoming transaction involving 2,199 shares of common stock associated with a stock option exercise, with Fidelity Brokerage Services LLC identified as the broker.
The notice also reports prior sales of Ceribell common stock by the same holder over the last three months, including 6,030 shares sold on May 21, 2026, and three separate blocks of 39,000 shares each sold on June 8, July 7, and August 3, 2026, with corresponding dollar amounts disclosed for each sale. The form is signed by an authorized representative of Fidelity Brokerage Services LLC acting as attorney-in-fact for the selling holder.
Ceribell, Inc. (CBLL) is the issuer of common stock that an affiliate, Scott E. Blumberg, has notified for potential sale under Rule 144. The notice covers 990 shares of common stock to be sold through Fidelity Brokerage Services LLC on or after 08/18/2026, with an indicated value of $24,750.00. The shares are to be acquired via a stock option exercise from the issuer for cash. In the prior three months, Blumberg previously sold 1,387 shares of Ceribell common stock on 05/21/2026 for proceeds of $24,960.31.
Ceribell, Inc. executive Xingjuan Chao, President and CEO, reported option exercises on August 13, 2026. She exercised stock options for 8,096 shares of common stock at an exercise price of $2.24 per share and for 25,000 shares at $3.65 per share, converting derivative awards into common stock. A separate holding entry shows 369,088 shares of common stock held indirectly by the ACP 2021 Trust, where she is co-trustee and may be deemed to share beneficial ownership, while disclaiming beneficial ownership except to the extent of her pecuniary interest.
Ceribell, Inc. received an amended Schedule 13G/A reporting that investment entities affiliated with TPG GP A, LLC, together with James G. Coulter and Jon Winkelried, collectively report beneficial ownership of 2,975,566 shares of Ceribell common stock. These shares are held directly by The Rise Fund Clearthought, L.P., over which TPG GP A exercises indirect control. Based on 38,378,101 shares of common stock outstanding as of August 6, 2026, the reported stake represents 7.8% of Ceribell’s common stock. The reporting persons share voting and dispositive power over these shares and disclaim beneficial ownership except to the extent of any pecuniary interest.
Ceribell, Inc. director Joseph Michael Taylor reported a sale of common stock. On 2026-08-13, he sold 13,095 shares of Ceribell common stock in a sale categorized as an open market or private transaction at $23.40 per share. Following this transaction, he directly holds 48,478 shares of Ceribell common stock.
CeriBell Inc insider Joseph Taylor filed to potentially sell shares of the company’s common stock. The notice lists up to 300,000 common shares to be sold through Sanford C. Bernstein & Co., LLC on or after August 13, 2026, with trading on Nasdaq. It also identifies common shares received as compensation from grants dated April 22, 2021 and August 14, 2018, totaling 3,204 and 13,064 shares, respectively, as securities to be sold for cash. In addition, the filing reports that during the past three months, on June 11, 2026, Taylor sold 5,500 common shares for proceeds of $101,255.00.
Ceribell, Inc. reported strong top-line growth but continued losses for the quarter and six months ended June 30, 2026. Total revenue rose to $28.1 million for the quarter and $54.6 million year-to-date, up 33% and 31% from 2025, driven by higher sales of disposable EEG Wearables and subscription fees as adoption expanded to more than 700 hospitals.
Gross margin improved to 92% in the quarter and 90% year-to-date, helped by scale and a $1.6 million IEEPA tariff refund. Operating expenses grew 36% year-to-date to $89.8 million, mainly from increased headcount, commercialization, and IP-related legal costs, leading to a net loss of $19.3 million for the quarter and $39.0 million year-to-date. The company held $129.3 million in cash, cash equivalents, and marketable securities and believes this will fund operations for at least 12 months. Subsequent to quarter-end, Ceribell refinanced its term loan with a new credit facility that includes a $30 million term loan commitment and a revolving line initially sized at $20 million, of which $20 million was drawn to repay the prior facility.
Ceribell, Inc. reported strong top-line growth for the quarter ended June 30, 2026. Total revenue was $28.1 million, up 33% from $21.2 million a year earlier, driven by new account additions and higher utilization across its installed base. Product revenue reached $21.2 million and subscription revenue $6.9 million, both rising about 30% year over year. The company ended the quarter with 712 active accounts.
Profitability remains negative but margins are high. Gross profit was $25.9 million with a 92% gross margin, aided by manufacturing efficiencies, a new Vietnam line, and one-time tariff refunds. Operating expenses increased 37% to $45.9 million as Ceribell invested in commercial expansion, R&D, and legal costs. Net loss widened to $19.3 million, or $0.51 per share, while Adjusted EBITDA loss was $9.8 million.
The balance sheet showed $129.3 million in cash, cash equivalents, and marketable securities at June 30, 2026. Ceribell subsequently entered a new credit facility providing access to up to $60 million in committed capital. The company raised its 2026 revenue outlook to $114–$117 million, implying about 28–31% growth. It also highlighted multiple FDA 510(k) clearances and a CMS New Technology Add-On Payment for its delirium monitoring solution, effective October 1, 2026.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of common stock of Ceribell Inc. FMR LLC and Abigail P. Johnson each report beneficial ownership of 5,691,393.03 shares, representing 15.0% of Ceribell’s common stock.
FMR LLC reports 5,688,542 shares with sole voting power and 5,691,393.03 shares with sole dispositive power, with no shared voting or dispositive power. One or more other persons may receive dividends or sale proceeds, but no such person has more than five percent of the class.
Ceribell, Inc. President and CEO Chao Xingjuan exercised stock options covering 25,000 shares of common stock at an exercise price of $4.70 per share and sold 39,000 common shares at a weighted average price of $18.32, in multiple trades between $17.88 and $18.72, pursuant to a Rule 10b5-1 trading plan.
An entity associated with her, the ACP 2021 Trust, holds 369,088 shares; she may be deemed to share beneficial ownership of these securities but disclaims beneficial ownership except to the extent of her pecuniary interest.